Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Regulation FD DisclosureItem 7.01.
The Company will present and post on its website an updated corporate presentation, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The foregoing information, including the presentation attached hereto as an exhibit, is being furnished to Item 7.01 of this Current Report and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement to the Securities Act of 1933, as amended
On September 20, 2017, Titan Pharmaceuticals, Inc. (the “Company”) announced that it will present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017. A copy of the press release issued by the Company is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
TITAN PHARMACEUTICALS INC ExhibitEX-99.1 2 v475481_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 © 2017 TITAN PHARMACEUTICALS INC. | NASDAQ:TTNP CORPORATE PRESENTATION | SEPTEMBER 2017 TITAN PHARMACEUTICALS The presentation may contain “forward – looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Reference is made in particular to the description of our plans and objectives for future operations,…To view the full exhibit click here
About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.